# ALCHEMIST Chemo-IO (NCT04267848)

> Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: resected stage II–IIIB non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04267848
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8
- Interventions: Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Echocardiography Test; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Observation Activity; Paclitaxel; Pembrolizumab; Pemetrexed Disodium; Questionnaire Administration
- Enrollment: 1210
- Primary outcome: Disease free survival (DFS)

## Indexed commentary on ALCHEMIST Chemo-IO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=alchemist-chemo-io-nct04267848